Filing Analysis
Vistagen Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the first quarter of fiscal year 2027, which ended on June 30, 2026.
📋 Key Facts
- Reporting period: Fiscal year 2027 first quarter ended June 30, 2026.
- Filing date: August 14, 2026.
- The filing is for the purpose of furnishing results via press release (Exhibit 99.1) rather than a formal SEC filing under Section 18.
Vistagen Therapeutics announced topline results from an exploratory Phase 2 repeat dose study of fasedienol for social anxiety disorder. While the study was not powered to demonstrate statistical significance, it showed numerical separation from placebo and nominal statistical significance in specific high-severity patient subgroups.
🚩 Red Flags
- The study was not designed to demonstrate statistically significant differences between treatment groups.
- Numerical trends in the total population did not reach statistical significance, which may impact regulatory pathway discussions.
- Potential for high variability and small sample size (N=61) impacting data reliability.
📋 Key Facts
- Study design: Three-arm, multicenter, randomized, double-blind, placebo-controlled exploratory Phase 2 trial (N=61).
- Primary endpoint analysis (SUDS score) showed numerical separation from placebo but failed to reach statistical significance in the total population.
- Subgroup analysis: Patients with very severe social anxiety (LSAS ≥95) showed nominally statistically significant responses for the single dose arm compared to placebo.
- Safety objective met: Repeat dose administration was comparable in safety and tolerability to single-dose administration.
- Secondary endpoints (CGI-I and PGI-C) were directionally higher for fasedienol than placebo, with repeat dose responder rates being more than twice that of placebo.
Vistagen Therapeutics received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share. The company must cure this deficiency by February 1, 2027, or face potential delisting.
🚩 Red Flags
- Delisting risk: The company is currently non-compliant with minimum bid price requirements.
- Potential for forced delisting if compliance is not met by February 1, 2027.
- History of non-compliance (previously disclosed deficiency on February 6, 2026).
📋 Key Facts
- Nasdaq granted a 180-day extension until February 1, 2027, to regain compliance with the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
- The deficiency stems from the common stock failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
- The company's listing remains fully effective during this extension period.
- Failure to regain compliance by the deadline will result in Nasdaq providing written notification of delisting, which may be subject to appeal.
Vistagen Therapeutics, Inc. announced the appointment of Douglas J. Williamson, M.D. to its Board of Directors effective July 29, 2026.
📋 Key Facts
- Douglas J. Williamson, M.D. appointed as a director on July 29, 2026.
- Term: Until the next annual meeting or until successor is elected/qualified.
- Compensation includes stock options to purchase up to 40,826 shares of common stock at an exercise price of $0.2433 per share.
- Options vest in equal annual installments over a three-year period starting one year from the Effective Date.
- Dr. Williamson entered into an Indemnification Agreement with the Company.
Vistagen Therapeutics announced that its PALISADE-4 Phase 3 trial for fasedienol failed to meet its primary endpoint in the treatment of social anxiety disorder. While a post-hoc analysis showed nominal significance in a severe subpopulation, the main study failed to demonstrate efficacy over placebo.
🚩 Red Flags
- Failure of a Phase 3 clinical trial for the lead candidate (fasedienol) is a major setback for biotech companies.
- Post-hoc analysis results are often viewed with skepticism by regulators and investors as they were not pre-specified.
📋 Key Facts
- PALISADE-4 Phase 3 trial failed to achieve the primary endpoint (LS mean change on SUDS score).
- Fasedienol LS mean change: -9.5 +/- 1.7 SE; Placebo LS mean change: -11.4 +/- 1.7 SE (p=0.427).
- No treatment difference was observed for secondary endpoints.
- Post-hoc analysis of a subpopulation with very severe social anxiety (LSAS >= 95, n=123) showed nominal significance: fasedienol -12.8 vs placebo -3.7 (p=0.036).
- Safety and tolerability data were consistent with previous trials.
- Company expects cash resources to support operations into 2027.
Vistagen Therapeutics announced that two members of its Board of Directors, Ms. Margaret FitzPatrick and Dr. Joanne Curley, have decided not to stand for re-election at the 2026 Annual Meeting of Stockholders.
📋 Key Facts
- Ms. Margaret FitzPatrick notified the company of her decision on June 16, 2026.
- Dr. Joanne Curley notified the company of her decision on June 17, 2026.
- Both directors will continue to serve until the conclusion of their terms at the 2026 Annual Meeting.
Vistagen Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the fiscal year ended March 31, 2026.
📋 Key Facts
- The filing date is June 15, 2026.
- The company announced financial results for the fiscal year ending March 31, 2026.
- The financial results were issued via a press release (Exhibit 99.1).
Vistagen Therapeutics announced that its clinical program for fasedienol nasal spray for social anxiety disorder has met the minimum patient exposure requirements as recommended by the ICH E1 international regulatory standard.
📋 Key Facts
- The announcement pertains to fasedienol nasal spray for the acute treatment of social anxiety disorder.
- The company has achieved minimum patient exposures per ICH E1 standards for drugs intended for long-term treatment of non-life-threatening conditions.
- The report was filed on June 9, 2026.
Vistagen Therapeutics, Inc. has appointed Dr. Angel S. Angelov as its new Chief Medical Officer, effective May 18, 2026. Dr. Angelov brings extensive psychiatric and clinical development experience from previous leadership roles at Theranica, Karuna Therapeutics, and Neurocrine Biosciences.
🚩 Red Flags
- The stock option exercise price of $0.5955 indicates the company's common stock is trading below $1.00, which poses a potential risk for Nasdaq minimum bid price compliance.
📋 Key Facts
- Dr. Angel S. Angelov, M.D., MBA, appointed as Chief Medical Officer effective May 18, 2026.
- Dr. Angelov's compensation includes a starting annual base salary of $425,000, a $50,000 signing bonus (paid in two tranches), and a target annual discretionary bonus of 45% of his base salary.
- Granted an inducement stock option to purchase 150,000 shares of common stock at an exercise price of $0.5955 per share, vesting over four years with a one-year cliff.
- Dr. Angelov previously served as CMO at Theranica and held medical affairs leadership roles at Karuna Therapeutics and Neurocrine Biosciences.
Vistagen Therapeutics announced preliminary positive data from the ongoing open-label extension of its PALISADE-3 Phase 3 clinical trial. The study evaluates fasedienol for the acute treatment of social anxiety disorder.
📋 Key Facts
- Preliminary positive data announced on May 12, 2026.
- The data originates from the open-label extension portion of the PALISADE-3 Phase 3 study.
- The drug candidate, fasedienol, is being developed for the acute treatment of social anxiety disorder.
- The company issued a press release (Exhibit 99.1) to disclose these findings.
Vistagen Therapeutics announced the completion of the last patient's last visit in its PALISADE-4 Phase 3 clinical trial. The trial evaluates fasedienol nasal spray for the acute treatment of social anxiety disorder.
📋 Key Facts
- The last patient completed their last visit in the PALISADE-4 Phase 3 clinical trial on May 8, 2026.
- The trial is a randomized, double-blind, placebo-controlled study.
- The study drug, fasedienol, is a nasal spray intended for the acute treatment of social anxiety disorder.
- The company issued a press release (Exhibit 99.1) regarding this milestone.
Vistagen Therapeutics received FDA clearance to proceed with Phase 2 clinical development of its refisolone nasal spray in the U.S. The candidate is a non-hormonal treatment for moderate to severe vasomotor symptoms (hot flashes) associated with menopause.
📋 Key Facts
- Received FDA 'Study May Proceed' letter on April 22, 2026, regarding its U.S. Investigational New Drug (IND) application.
- The product candidate, refisolone nasal spray, is non-hormonal and non-systemic.
- The U.S. Phase 2 development follows successful exploratory Phase 2a studies previously conducted in Mexico.
- The target indication is moderate to severe vasomotor symptoms (hot flashes) due to menopause and premenstrual dysphoric disorder.
Vistagen Therapeutics approved broad-based retention stock option awards for all employees, including five key executive officers, on April 7, 2026. The awards feature a two-year vesting schedule and an exercise price of $0.5358 per share.
🚩 Red Flags
- The exercise price of $0.5358 indicates the stock is trading significantly below the Nasdaq $1.00 minimum bid price requirement, suggesting potential delisting risk.
- Broad-based 'retention' awards often signal internal concerns regarding employee turnover or low morale following share price depreciation.
📋 Key Facts
- Retention awards granted to all employees on April 7, 2026.
- Five named executive officers (CEO, CLO, CCDO, COO, and CFO) each received options for 75,000 shares.
- The exercise price is set at $0.5358 per share.
- Vesting occurs in 25% increments every six months, reaching full vestment on the two-year anniversary.
- The grants were issued under the Company’s Amended and Restated 2019 Omnibus Equity Incentive Plan.
Vistagen Therapeutics notified Nasdaq of non-compliance with Audit Committee requirements following the resignation of director Mary Rotunno. The company currently has only two members on its Audit Committee, falling below the Nasdaq requirement of three independent members.
🚩 Red Flags
- Failure to satisfy Nasdaq continued listing standards regarding board composition.
- Loss of a director (Mary Rotunno) resulting in governance non-compliance.
📋 Key Facts
- The Company notified Nasdaq of non-compliance with Listing Rule 5605(c)(2) on April 1, 2026.
- The non-compliance was triggered by the resignation of Mary Rotunno from the Board, effective April 1, 2026.
- The Audit Committee currently has two members, whereas Nasdaq requires at least three.
- The Company has a cure period to regain compliance, which expires at the earlier of the next annual meeting or April 1, 2027.
- The listing of the Company's common stock on The Nasdaq Capital Market is not immediately affected.
On March 17, 2026, Mary Rotunno resigned from the Board of Directors of Vistagen Therapeutics, Inc., effective April 1, 2026.
📋 Key Facts
- Mary Rotunno resigned from the Board of Directors on March 17, 2026.
- The resignation is scheduled to become effective on April 1, 2026.
- The filing does not disclose any disagreements between the director and the company.
Vistagen Therapeutics, Inc. furnished a new corporate presentation dated March 2026 under Regulation FD. This filing is a routine update of investor materials and does not report any material changes to operations or financial status.
📋 Key Facts
- The filing was made on March 16, 2026, under Item 7.01 Regulation FD Disclosure.
- The primary purpose is the release of a new corporate presentation (Exhibit 99.1).
- The information provided is 'furnished' and not 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by CEO Shawn K. Singh.
Vistagen Therapeutics announced a 20% workforce reduction to preserve cash and prioritize its Phase 3 clinical program for fasedienol. The company expects topline results from its PALISADE-4 trial in H1 2026 and projects its cash runway will last into 2027.
🚩 Red Flags
- 20% workforce reduction indicates significant cost-cutting necessity.
- Concentration of resources on a single clinical program increases binary risk.
📋 Key Facts
- Implemented a 20% reduction in workforce on March 5, 2026.
- Prioritizing the PALISADE Program for fasedienol in social anxiety disorder.
- Topline results from PALISADE-4 Phase 3 trial expected in the first half of 2026.
- Projected cash runway extends into 2027.
- Severance and healthcare costs associated with the layoff are expected to be immaterial.
Vistagen Therapeutics disclosed the resignation of board director Paul Edick effective February 13, 2026. No reason was provided for the departure. The company stated it is actively seeking candidates to fill the resulting board vacancy.
🚩 Red Flags
- No reason provided for the board resignation — absence of standard 'no disagreement' language raises governance questions
- 7-day delay between resignation event (Feb 13) and filing date (Feb 20), though within the 4 business day SEC requirement
📋 Key Facts
- Paul Edick resigned from the Board of Directors on February 13, 2026
- No reason or context was provided for the resignation
- Company is actively seeking new candidates to fill the board vacancy
- Filing signed by CEO Shawn K. Singh on February 20, 2026 (7-day gap between event and filing)
- VTGN is listed on Nasdaq Capital Market, incorporated in Nevada, headquartered in South San Francisco
Vistagen Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal year 2026 third quarter ended December 31, 2025.
📋 Key Facts
- Reporting date: February 12, 2026
- Period covered: Fiscal year 2026 third quarter (ended December 31, 2025)
- The filing is intended to furnish results via press release (Exhibit 99.1) rather than as a formal 'filed' document under Section 18.
Vistagen Therapeutics received a notice from Nasdaq indicating the company is in violation of the minimum bid price requirement ($1.00 per share) for continued listing on the Nasdaq Capital Market.
🚩 Red Flags
- Delisting notice from Nasdaq regarding minimum bid price requirement.
- Stock has been trading below $1.00 for at least 30 consecutive business days, indicating significant downward momentum or lack of investor interest.
📋 Key Facts
- Received Nasdaq Notice on February 3, 2026.
- Violation: Closing bid price was below $1.00 for the last 30 consecutive business days (Nasdaq Listing Rule 5550(a)(2)).
- Compliance Period: The company has a 180-calendar day period starting February 3, 2026, to regain compliance.
- Requirement to Regain Compliance: Must maintain a closing bid price of at least $1.00 for 10 consecutive business days before August 6, 2026.
- Potential Extension: A second 180-day period may be granted if the company meets other Nasdaq market value and listing standards.
Vistagen Therapeutics, Inc. filed an 8-K to announce the adoption of a new corporate presentation dated January 2026.
📋 Key Facts
- The company began utilizing a new corporate presentation on January 9, 2026.
- The filing includes Exhibit 99.1 containing the updated presentation.
- Information provided under Item 7.01 is furnished but not filed for purposes of Section 18 liability.
Vistagen Therapeutics announced that its PALISADE-3 Phase 3 clinical study for fasedienol in treating social anxiety disorder failed to meet its primary endpoint. The study showed no significant difference between fasedienol and placebo regarding Subjective Units of Distress Scale scores.
🚩 Red Flags
- Failure of a Phase 3 clinical trial is a major setback for a biotech company, often impacting valuation and runway significantly.
- Lack of efficacy in the primary endpoint suggests potential failure of the lead asset's path to regulatory approval.
📋 Key Facts
- PALISADE-3 Phase 3 study failed to achieve the primary endpoint for intranasal fasedienol in social anxiety disorder.
- LS mean change from baseline on Subjective Units of Distress Scale: fasedienol (13.6 +/-1.54 SE) vs. placebo (14.0 +/-1.51 SE).
- No treatment difference was observed for secondary endpoints.
- Safety data remained favorable and consistent with previous clinical trials.
Vistagen Therapeutics, Inc. has appointed Nick B. Tressler as the new Chief Financial Officer (CFO), Treasurer, and principal financial/accounting officer, effective December 1, 2025. This appointment concludes the interim role held by CEO Shawn K. Singh.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Nick B. Tressler appointed CFO and Treasurer effective Dec 1, 2025.
- Annual base salary set at $450,000 with a $50,000 signing bonus.
- Target annual discretionary cash bonus of 45% of base salary.
- Inducement grant of up to 150,000 stock options with an exercise price of $4.43 per share.
- Options vest over a 4-year period (1-year cliff followed by 36 months monthly).
- Shawn K. Singh will cease serving as interim principal financial and accounting officer upon the new appointment.
Vistagen Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal year 2026 second quarter ended September 30, 2025.
📋 Key Facts
- Reporting period: Fiscal year 2026 second quarter ended September 30, 2025.
- Filing date: November 13, 2025.
- The filing is a standard earnings release under Item 2.02.
Vistagen Therapeutics announced the completion of the public speaking challenge portion of its PALISADE-3 Phase 3 clinical trial for fasedienol. This marks a key milestone in the evaluation of the drug for treating social anxiety disorder.
📋 Key Facts
- The last patient has completed the randomized, double-blind, placebo-controlled public speaking challenge portion of the PALISADE-3 Phase 3 clinical trial.
- The trial is evaluating fasedienol for the acute treatment of social anxiety disorder.
- Announcement date: November 3, 2025.
Vistagen Therapeutics, Inc. announced the appointment of Paul R. Edick to its Board of Directors, effective October 27, 2025. Mr. Edick will serve on the Audit and Compensation Committees.
📋 Key Facts
- Paul R. Edick appointed as director on October 27, 2025.
- Mr. Edick to serve on the Audit and Compensation Committees of the Board.
- Compensation includes stock options for up to 35,200 shares at an exercise price of $3.90 per share.
- Options vest in equal annual installments over a three-year period starting one year from the effective date.
- The appointment was recommended by the Corporate Governance and Nominating Committee.
Vistagen Therapeutics announced the resignation of its CFO, Cynthia L. Anderson, effective October 15, 2025. The company also reported results from its 2025 Annual Meeting of Stockholders, including the election of directors and ratification of KPMG LLP as auditors.
🚩 Red Flags
- Departure of a key C-suite officer (CFO) during an active development phase.
📋 Key Facts
- Cynthia L. Anderson (CFO) to resign effective October 15, 2025.
- The resignation is not due to any disagreement regarding company operations or practices.
- Company will enter into a consulting agreement with the outgoing CFO to support the transition.
- Six director nominees were elected to serve until the 2026 Annual Meeting.
- Stockholders approved 'Say-on-Pay' advisory vote on executive compensation.
- KPMG LLP was ratified as independent auditors for fiscal year ending March 31, 2026.
Vistagen Therapeutics, Inc. filed an 8-K to announce its fiscal year 2026 first quarter financial results for the period ended June 30, 2025. The company also updated its corporate presentation.
📋 Key Facts
- Announced Q1 FY2026 financial results (period ended June 30, 2025) via press release.
- Released a new corporate presentation dated August 2025.
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Vistagen Therapeutics, Inc. announced the appointment of Elissa Cote as Chief Corporate Development Officer, effective June 23, 2025. The move brings experienced biopharmaceutical leadership to the company's strategic and transactional operations.
📋 Key Facts
- Elissa Cote appointed as Chief Corporate Development Officer effective June 23, 2025.
- Ms. Cote previously held senior roles at Mallinckrodt Pharmaceuticals and MedImmune Inc. (AstraZeneca).
- The appointment includes an Indemnification Agreement between the Company and Ms. Cote.
- No related party transactions were disclosed in connection with this appointment.
Vistagen Therapeutics announced its fiscal year 2025 financial results and filed a prospectus supplement to increase the aggregate offering price of common stock under an existing shelf registration via an At-The-Market (ATM) sales agreement.
🚩 Red Flags
- Significant increase in potential dilution: The company is expanding its ability to sell common stock by an additional $75M (from $100M to $175M total capacity).
- Continuous use of ATM offerings often indicates a need for immediate liquidity to fund operations, typical in biotech companies with high burn rates.
📋 Key Facts
- Company issued press release for fiscal year ended March 31, 2025 results.
- Filed a prospectus supplement under Form S-3 shelf registration (File No. 333-277041).
- Increased aggregate offering price capacity to $175,000,000 via an Open Market Sale Agreement with Jefferies LLC.
- Prior prospectus supplement had a cap of $100,000,000; previous sales totaled approximately $3,443,612 from 1,273,883 shares.
- Remaining capacity under the new Prospectus Supplement is up to $171,556,388.
Vistagen Therapeutics issued a press release providing clinical trial timeline updates for its PALISADE Phase 3 Program evaluating fasedienol. The company also released an updated corporate presentation.
📋 Key Facts
- PALISADE-3 Phase 3 clinical trial topline data expected in Q4 2025.
- PALISADE-4 Phase 3 clinical trial topline results expected in H1 2026.
- The company is evaluating fasedienol for the acute treatment of social anxiety disorder.
Vistagen Therapeutics disclosed a civil class-action lawsuit filed by two individuals alleging securities fraud related to misleading statements about clinical trials. The company also announced participation in upcoming healthcare conferences.
🚩 Red Flags
- Securities litigation alleging material omissions regarding clinical trial data (highly relevant for biotech micro-caps).
- Broad defendant list including Board members and external advisors increases potential legal complexity and cost.
- Allegations of 'misleading statements' can trigger regulatory scrutiny beyond the civil suit.
📋 Key Facts
- On February 13, 2025, John Cesario and David Preka filed a pro se civil action in the U.S. District Court for the Northern District of California (Case No. 4:25-cv-01510).
- Plaintiffs seek compensatory and punitive damages, as well as fees and costs.
- Allegations include violations of Section 10(b) of the Exchange Act and Sections 11 and 17(a) of the Securities Act regarding misleading statements/omissions about clinical trials.
- The lawsuit names the Company, Board of Directors, certain executive officers, professional services, financial advisors, and industry analysts as defendants.
- Company stated it believes allegations are 'wholly without merit' and intends to defend vigorously.
- Company presented at the 45th Annual TD Cowen Healthcare Conference on March 3, 2025.
Vistagen Therapeutics, Inc. filed an 8-K to furnish its third quarter fiscal year 2025 financial results and a new corporate presentation.
📋 Key Facts
- Reported date: February 13, 2025
- Reporting period: Fiscal year 2025 third quarter ended December 31, 2024
- The company issued a press release containing financial results (Exhibit 99.1)
- The company released an updated corporate presentation (Exhibit 99.2)
Vistagen Therapeutics announced that the U.S. Patent and Trademark Office has granted a patent for its oral non-opioid product candidate, AV-101, intended for treating neuropathic pain. The patent provides intellectual property protection through at least 2034.
📋 Key Facts
- Patent granted by the U.S. Patent and Trademark Office for AV-101 (oral non-opioid candidate).
- Indicated therapeutic use: treatment of neuropathic pain.
- Patent expiration date: at least 2034.
- The patent covers manufacturing methods and therapeutic uses involving the NMDA receptor.
Vistagen Therapeutics announced positive results from an exploratory Phase 2A study of its investigational nasal spray, PH284, targeting cancer cachexia. The study indicated improved hunger levels and a safety profile comparable to placebo in terminal cancer patients.
📋 Key Facts
- Phase 2A exploratory study for PH284 (pherine nasal spray) was conducted for the treatment of cancer cachexia.
- PH284 demonstrated higher mean subjective feeling of hunger compared to placebo.
- The drug appeared safe and well-tolerated with an adverse event profile similar to placebo.
- Study population consisted of patients compromised by terminal cancer.
Vistagen Therapeutics announced the enrollment of the first subject in an exploratory repeat dose study for its investigational drug, fasedienol. This study is part of the company's Phase 3 development program targeting social anxiety disorder.
📋 Key Facts
- First subject enrolled in an exploratory repeat dose study of fasedienol as of January 10, 2025.
- The study is part of the U.S. Phase 3 development program for fasedienol.
- Target indication: acute treatment of social anxiety disorder.
Vistagen Therapeutics, Inc. filed an 8-K to announce the adoption of a new corporate presentation as of December 6, 2024.
📋 Key Facts
- The company began utilizing a new corporate presentation on December 6, 2024.
- The filing includes Exhibit 99.1 containing the updated corporate presentation dated December 2024.
Vistagen Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal year 2025 second quarter ended September 30, 2024.
📋 Key Facts
- The filing is a routine announcement of financial results (Item 2.02).
- Reporting period: Fiscal year 2025 second quarter ended September 30, 2024.
- Filing date: November 7, 2024.
Vistagen Therapeutics announced the enrollment of the first subject in its PALISADE-4 Phase 3 clinical trial for fasedienol, intended for the treatment of social anxiety disorder. This represents a key milestone in the company's late-stage clinical development program.
📋 Key Facts
- First subject enrolled in the PALISADE-4 Phase 3 trial on September 23, 2024.
- The trial is for fasedienol, an investigational neuroactive pherine candidate.
- The study is a U.S. registration-directed Phase 3 development program.
- Target indication: acute treatment of social anxiety disorder.
Vistagen Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on August 26, 2024. The company successfully elected seven directors, approved executive compensation on an advisory basis, and ratified the appointment of KPMG LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on August 26, 2024.
- All seven director nominees were elected to serve until the 2025 Annual Meeting: Margaret M. FitzPatrick, Ann M. Cunningham, Joanne Curley, Jerry B. Gin, Mary L. Rotunno, Jon S. Saxe, and Shawn K. Singh.
- Stockholders approved 'Say-on-Pay' advisory vote for executive compensation (13,758,902 votes in favor).
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2025.
Vistagen Therapeutics, Inc. filed an 8-K to furnish its quarterly press release regarding financial results for the fiscal year 2025 first quarter ended June 30, 2024.
📋 Key Facts
- The filing reports on the fiscal year 2025 first quarter ended June 30, 2024.
- The company issued a press release (Exhibit 99.1) containing financial results.
- Report date: August 13, 2024.
Vistagen Therapeutics has dismissed its independent auditor, WithumSmith+Brown, PC, and appointed KPMG LLP as its new independent registered public accounting firm effective July 8, 2024. The change follows a competitive selection process by the Audit Committee.
🚩 Red Flags
- Auditor change (Dismissal of Withum)
- Historical presence of 'going concern' language in the FY 2023 audit report (though resolved in FY 2024).
📋 Key Facts
- Dismissal of WithumSmith+Brown, PC (Withum) effective July 8, 2024.
- Engagement of KPMG LLP as the new independent auditor for the fiscal year ending March 31, 2025.
- The company stated there were no disagreements with Withum regarding accounting principles or auditing procedures.
- Withum's audit report for FY ended March 31, 2023, included a going concern explanatory paragraph, but the FY 2024 report did not.
Vistagen Therapeutics announced the expansion of its global intellectual property portfolio through multiple new patents related to PH80 for migraine treatment. This follows existing development efforts for PH80 as a treatment for vasomotor symptoms.
📋 Key Facts
- Received multiple new patents regarding the use of PH80 for migraine treatment.
- PH80 is an investigational pherine nasal spray being developed for vasomotor symptoms (hot flashes).
- Potential indications for PH80 include premenstrual dysphoric disorder, dysmenorrhea, and migraine.
Vistagen Therapeutics announced it has received the Mental Health America (MHA) 2024 Platinum Bell Seal for Workplace Mental Health. This is a non-financial recognition of the company's workplace mental health initiatives.
📋 Key Facts
- Awarded the MHA 2024 Platinum Bell Seal for Workplace Mental Health on June 27, 2024.
- The award is described as MHA’s highest honor regarding workplace well-being.
Vistagen Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal year ended March 31, 2024.
📋 Key Facts
- Report date: June 11, 2024
- Reporting period: Fiscal year ended March 31, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were issued via press release as Exhibit 99.1
Vistagen Therapeutics, Inc. announced the successful outcome of a special meeting of stockholders held on May 29, 2024. Stockholders approved two amendments to existing equity incentive and employee stock purchase plans.
📋 Key Facts
- Special Meeting held on May 29, 2024.
- Proposal No. 1: Amendment to the 2019 Omnibus Equity Incentive Plan was approved with 82.0% of votes cast in favor.
- The 2019 Plan Amendment increases authorized shares under the plan from 1,000,000 to 5,000,000.
- Proposal No. 2: Amendment to the 2019 Employee Stock Purchase Plan (ESPP) was approved with 82.3% of votes cast in favor.
- The ESPP Amendment increases authorized shares from 33,334 to 1,000,000.
Vistagen Therapeutics announced its intention to present scientific posters at the American Society of Clinical Psychopharmacology Conference regarding its lead drug candidates, fasedienol and itruvone.
📋 Key Facts
- Company will present posters for fasedienol (Phase 3 development for social anxiety disorder) at the conference in Miami Beach, FL.
- Company will present posters for itruvone (Phase 2 development for major depressive disorder) at the conference in Miami Beach, FL.
- Conference dates: May 28 to May 31, 2024.
Vistagen Therapeutics announced positive Phase 2A pilot study results for its investigational nasal spray, PH15. The study showed statistically significant improvements in reaction time for sleep-deprived participants compared to placebo and caffeine.
📋 Key Facts
- PH15 is an investigational pherine nasal spray designed to improve psychomotor impairment caused by mental fatigue.
- The Phase 2A pilot study was randomized, double-blind, placebo-controlled, and crossover in design.
- Results demonstrated statistically significant improvement in reaction time compared to both placebo and caffeine in sleep-deprived participants.
- The announcement was made via press release on April 25, 2024.
Vistagen Therapeutics announced the enrollment of the first patient in its PALISADE-3 Phase 3 clinical trial for fasedienol, intended for the acute treatment of social anxiety disorder.
📋 Key Facts
- First patient enrolled in the PALISADE-3 Phase 3 trial on April 1, 2024.
- The drug candidate is fasedienol, an investigational pherine.
- Target indication: acute treatment of social anxiety disorder.
Vistagen Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal year 2024 third quarter ended December 31, 2023.
📋 Key Facts
- Reporting period: Fiscal year 2024 third quarter ended December 31, 2023.
- Filing date: February 13, 2024.
- The filing consists of a press release (Exhibit 99.1) regarding results of operations and financial condition.
Vistagen Therapeutics, Inc. filed an 8-K to announce the adoption of a new corporate presentation dated January 2024.
📋 Key Facts
- The filing was triggered by the use of a new corporate presentation (Exhibit 99.1).
- Report date: January 8, 2024.
- The information in Exhibit 99.1 is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Vistagen Therapeutics announced that the European Patent Office has issued a Notice of Intention to Grant a patent for the use of its drug candidate AV-101 in treating neuropathic pain. This expands the company's intellectual property protections for AV-101 through at least 2034.
📋 Key Facts
- European Patent Office issued a Notice of Intention to Grant a patent related to AV-101.
- The patent covers the use of AV-101 (an oral NMDAR glycine site antagonist) for neuropathic pain treatment.
- The patent protection is expected to last until at least 2034.
- Event occurred on December 27, 2023.